Food and Drug Administration
Center for Drug Evaluation and Research
Summary Minutes of the Orally Inhaled and Nasal Drug Products Subcommittee
of the Advisory Committee for Pharmaceutical Science
July 17, 2001
CDER Advisory Committee Conference Room
5630 Fishers Lane
Members Present Executive Secretary
Vincent H. L. Lee, Ph.D., Acting Chair Nancy Chamberlin, PharmD.
Consumer Representative FDA
Gloria L. Anderson, Ph.D. Wallace P. Adams, Ph.D.
. Badrul Chowdhury, M.D.,Ph.D.
Invited SGE Consultant Dale P. Conner, PharmD.
Richard C. Ahrens, M.D. Robert J. Meyer, M.D.
Mark S. Dykewicz, M.D. Guirag Poochikin, Ph.D.
Leslie S. Hendeles, PharmD., F.C.C.P. Gur Jai Pal Singh, Ph.D.
Dennis R. Ownby, M.D. Helen N. Winkle
Invited Guests Participants Invited Industry Guests
Walter W. Hauck, Ph.D. Izabela J. Roman, M.D., Ph.D.
Leon Shargel, Ph.D., R.Ph.
These summary minutes for the July 17, 2001 meeting of the Orally Inhaled and Nasal Drug Products Subcommittee of the Advisory Committee for Pharmaceutical Sciences were approved on September 25, 2001.
I certify that I attended the July 17, 2001 of the Orally Inhaled and Nasal Drug Products Subcommittee of the Advisory Committee for Pharmaceutical Sciences and that these minutes accurately reflect what transpired.
Nancy Chamberlin, Pharm.D. Vincent H. L. Lee, Ph.D.
Executive Secretary Acting Chair
Summary Minutes of the July 17, 2001 of the Orally Inhaled and Nasal Drug Products Subcommittee of the Advisory Committee for Pharmaceutical Science
On July 17, 2001, the Orally Inhaled and Nasal Drug Products Subcommittee of the Advisory Committee for Pharmaceutical Science met in an open public session at the CDER Advisory Committee Conference Room, 5630 Fishers Lane, Rockville, Maryland. Prior to the meeting, the members, consultants and invited guests had reviewed background material from the FDA. There were approximately 120 people in attendance.
At 8: 34 a.m., the meeting was called to order by, Vincent H. L. Lee, Ph.D., Acting Chair. This
was followed by the conflict of interest statement, read by Nancy Chamberlin, PharmD.,
Executive Secretary, and the introduction of meeting participants.
Helen Winkle introduced the topics and presented FDA’s objectives for the meeting.
Dale P. Conner, PharmD., provided an overview in his presentation of Bioequivalence
Considerations for Locally Acting Nasal Drug Products. Then Wallace P. Adams, Ph.D.,
presented on The June 1999 BA/BE Guidance for Nasal Aerosols and Nasal Sprays: History,
Recommendations and Local Delivery Issues. This was followed by Badrul Chowdhury, M.D.,
Ph.D.’s presentation of Difficulties in Showing a Dose-Response with Locally-Acting Nasal
Sprays and Aerosols for Allergic Rhinitis. Then Robert J. Meyer, M.D., presented on Clinical
Study Options for Locally Acting Nasal Suspension Products.
Following the presentations was the subcommittee discussion regarding clinical BE studies for
comparison of local delivery of suspension nasal products for allergic rhinitis.
Open Public Hearing Session:
The AAPS Inhalation Technology Focus Group (ITFG)/ International Pharmaceutical Aerosol Consortium (IPAC) Collaboration Technical Teams representatives presented information on Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products. Cynthia L. Flynn, Ph.D., RWJ-PRI, presented Review of CMC OINDP Issues Addressed by ITFG/IPAC-RS Collaboration. Then Joel Sequeira, Ph.D., Schering Plough Research Institute, presented the Review of BA/BE Team's Work; Team's Comments on Issue of Dose Response.
Finally Piyush Patel, M.D., F.R.C.P. (C), Allied Clinical Research, Inc. presented on the Environmental Exposure Chamber, and the Design of a Pilot Study to Determine Dose Response and Response Variability with Topical Nasal Steroids.
The meeting adjourned on July 17, 2001 at 3:20 p.m.
For more detailed information see the verbatim transcript of this meeting on the FDA’s Docket Management Branch Website address:
Nancy Chamberlin, PharmD., Executive Secretary
Orally Inhaled and Nasal Drug Products Subcommittee of the Advisory Committee for Pharmaceutical Science